# Tianjin Chase Sun Pharmaceutical

Tianjin Chase Sun Pharmaceutical is a Corporate Investor based in Tianjin, China.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Tianjin, China
- **Region:** Asia
- **Address:** Wuqing Development Zone, Tianjin, China
- **Founded:** 1996
- **Assets under management:** Undisclosed
- **Website:** chasesun.cn
- **LinkedIn:** https://www.linkedin.com/company/tianjin-chase-sun-pharmaceutical-co-ltd

## Regulatory record

- **Reports private funds:** No

## About

Tianjin Chase Sun Pharmaceutical was established in 1996 by Wang Jiang, who retains a roughly 15% individual stake while the state-owned Chengdu Xingcheng Investment Group serves as controlling shareholder. Wenyuan Wu chairs the board, and Wujun Lan runs day-to-day operations as Vice Chairman and General Manager. The firm is headquartered in Tianjin's Wuqing Development Zone and maintains a commercial office in Glen Iris, Victoria, Australia. The firm operates across biomedicine and medical equipment, with an investment posture rooted in traditional Chinese medicine (TCM) herbs and modern pharmaceutical production. Its industrial footprint includes a dedicated pharmaceutical production facility at 17 Yuanquan Road in the Wuqing Development Zone and a technology transfer center on the same campus. The controlling shareholder, Chengdu Xingcheng Investment Group, ties Chase Sun to municipal state capital, giving it access to policy-aligned healthcare initiatives within China. Team size and aggregate deployment figures are not publicly reported. Chase Sun's structural differentiator is its position as a publicly listed corporate investor majority-controlled by a state entity while retaining a significant founder stake — an architecture that combines state policy tailwinds with entrepreneurial continuity.

## Sectors

- Healthcare Services
- Digital Health

## Offices

- Melbourne, Australia

## People

- Wenyuan Wu — Chairman of the Board
- Wujun Lan — Vice Chairman and General Manager
- Wang Jiang — Founder and significant individual shareholder

## Questions

### Who controls Tianjin Chase Sun Pharmaceutical?

Chengdu Xingcheng Investment Group, a state-owned entity, is the controlling shareholder. Founder Wang Jiang holds a significant minority stake of approximately 15%. Wenyuan Wu serves as Chairman of the Board, and Wujun Lan is Vice Chairman and General Manager.

### How does Tianjin Chase Sun Pharmaceutical deploy capital?

The firm deploys capital through direct corporate investment in biomedicine and medical equipment, supplemented by ownership of physical assets including a pharmaceutical production facility, a technology transfer center, and a traditional Chinese medicine herb operation. Its deployment model is that of a corporate investor rather than a fund-based structure.

## Related profiles

- [Tianjin Binhai New Area Venture Capital Guiding Fund](https://altss.com/profile/tianjin-binhai-new-area-venture-capital-guiding-fund)
- [Tianjin Haikai Xinchuang Industry Development](https://altss.com/profile/tianjin-haikai-xinchuang-industry-development)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/tianjin-chase-sun-pharmaceutical

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology